Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported on 10/03/2025 an acquisition of 134.1686 deferred stock units at an indicated price of $20.64. After the transaction, Mr. Simmons is recorded as beneficially owning 17,970.3106 shares (or share equivalents). The deferred stock units represent the right to receive one share each or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Elanco Animal Health Inc. (ELAN) reported insider awards to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen. The Form 4 discloses a grant of 109,857 restricted stock units that vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028. The filing also shows a grant of 53,869 employee stock options with an exercise price of $20.80, exercisable beginning in the same three-tranche schedule and expiring on October 1, 2035. Both holdings are reported as direct ownership following the transactions. The Form 4 was signed by an attorney-in-fact on behalf of Mr. VanHimbergen and lists the transaction date as October 1, 2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc (ELAN), reported an acquisition of 144.2313 deferred stock units on 09/19/2025. Each deferred stock unit represents the right to one share of common stock or the cash equivalent and settles in cash or shares under the company’s Executive Deferral and Stock Match Plan. The reported transaction used transaction code A (acquisition) at an indicated underlying price of $19.20 per share, and following the transaction Mr. Simmons beneficially owns 17,836.142 shares directly. The Form 4 was signed on behalf of Mr. Simmons by Amy C. Seidel as attorney-in-fact on 09/23/2025.
Rajeev A. Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), acquired 73.6781 deferred stock units on 09/19/2025 under the companys Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and such units settle in cash or shares following termination of employment or in a specified future year. After the reported transaction Mr. Modi beneficially owned 6,964.7245 units (directly).
The units were reported with an indicated price of $19.20 per underlying share. The filing was signed by an attorney-in-fact on behalf of Mr. Modi and notes his officer role; no other material transactions or additional context are included.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), acquired 150.2572 deferred stock units on 09/05/2025 at an attributable price of $18.43 each. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Following this transaction, Mr. Simmons' beneficial ownership is reported as 17,691.9107 shares (direct). The Form 4 was signed by an attorney-in-fact on 09/09/2025. No other cash purchases, sales, or derivative exercises are reported in this filing.
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported a Section 16 transaction on 09/05/2025. The filing records an acquisition of 76.7564 deferred stock units (DSUs) at an indicated price of $18.43 per unit. Each DSU represents the right to receive one share of common stock or the cash equivalent and DSUs settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. The report shows 6,891.0464 shares beneficially owned following the transaction. The Form 4 was signed by Amy C. Seidel as attorney-in-fact on 09/09/2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported an acquisition on 08/22/2025 of 154.6198 deferred stock units. Each deferred stock unit represents the right to one share of common stock or a cash equivalent and the units were priced at $17.91 per underlying share for reporting purposes. Following the reported transaction, Mr. Simmons beneficially owned 17,541.6535 shares (or economic equivalents) of Elanco common stock. The deferred stock units will settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. The Form 4 was signed on behalf of Mr. Simmons by an attorney-in-fact on 08/26/2025.
Elanco Animal Health insider transaction: The Form 4 reports that Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, was granted 78.9849 deferred stock units on 08/22/2025. Each deferred stock unit represents the right to receive one share of Elanco common stock or a cash equivalent. The filing shows an exercise/reference price of $17.91 and indicates Mr. Modi beneficially owns 6,814.29 shares (or units) following the reported transaction. The deferred units will settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc.'s President, CEO and Director Jeffrey N. Simmons acquired 166.1212 deferred stock units on 08/08/2025 under the company's Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. After the reported acquisition, Mr. Simmons beneficially owns 17,387.0337 common stock-equivalent units on a direct basis. The deferred units may settle in cash or shares following termination of employment or during a specified future year.
This Form 4, filed for Elanco Animal Health Inc. (ELAN), reports that Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, had a transaction dated 08/08/2025. The filing shows acquisition of deferred stock units with a recorded amount of 6,735.3051 (displayed in the form) and a price field showing $16.67. The form notes each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and that units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan. The filing was signed by Amy C. Seidel as attorney-in-fact on 08/12/2025 and was filed by one reporting person.